Biosonics, Inc., Launches Marketing Campaign for Salitron.FORT WASHINGTON, Pa.--(BW HealthWire)--Aug. 24, 1999-- Biosonics, Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: BISN), the Fort Washington, PA-based company that specializes in electrotherapeutic solutions, will launch a marketing campaign in the Philadelphia tri-state area to physicians and dentists for its Salitron, an electrotherapeutic device to naturally and safely treat dry mouth. Schiff Marketing Concepts, of Wayne, PA, and Rubin Public Relations public relations, activities and policies used to create public interest in a person, idea, product, institution, or business establishment. By its nature, public relations is devoted to serving particular interests by presenting them to the public in the most , of Narberth, PA, are coordinating the marketing campaign with Biosonics. Biosonics Vice President Sandra Pileggi said the campaign is part of a program to identify, educate and inform physicians, and other health professionals, on the benefits of the Salitron, which has been approved for marketing by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. . "In addition to the marketing campaign, we are surveying about 300 current users of the Salitron to establish patient usage, satisfaction and progress," said Karen Fonville, Biosonics' manager of medical sales. "As part of the marketing plan, we will also be contacting physicians to introduce this new alternative therapy device." Dry mouth occurs as a result of Sjogren's Syndrome Sjö·gren's syndrome n. A syndrome occurring in menopausal women, characterized by keratoconjunctivitis sicca, dryness of mucous membranes, telangiectasias or purpuric spots on the face, and bilateral parotid enlargement; it is often associated with , head and neck radiation, drug therapy and other unknown cases. It can reduce a person's quality of life drastically, since lack of saliva may cause difficult swallowing and eating, inability to taste or smell, rampant dental problems and halitosis halitosis (hăl'ĭtō`sĭs), unpleasant odor carried on the breath. It is usually the result of gum disorder, tooth decay, smoking, indulgence in aromatic foods, or a mild digestive upset. . The Salitron is an electrotherapeutic device designed to stimulate the flow of saliva through cranial nerve cranial nerve n. Any of 12 pairs of nerves that emerge from or enter the brain, comprising the olfactory (I), optic (II), oculomotor (III), trochlear (IV), trigeminal (V), abducent (VI), facial (VII), vestibulocochlear (VIII), glossopharyngeal (IX), pathways. It is currently the only natural alternative to medications, since it produces no side effects. It is estimated that millions of people throughout the world suffer from dry mouth. Biosonics estimates the potential US market to be $75 million with a 10 percent market share. In addition to the Salitron, Biosonics has FDA marketing approval for the Cystotron, a device to treat incontinence (+13 million people). Biosonics has also developed several patented medical products that incorporate the same technology as the approved products, for medical conditions such as erectile dysfunction (+20 million men) and nasal/sinus congestion The condition of a network when there is not enough bandwidth to support the current traffic load. congestion - When the offered load of a data communication path exceeds the capacity. (+50 million people), as well as diagnostic tools for physicians. All statements contained in the press release are not historical facts, including but not limited to the Company's plans for products development and marketing, are based on current expectations. These statements are forward looking (as defined in the US Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 and the Act) in nature and involve a number of rises and uncertainties. The factors that could cause actual results to vary materially include the availability of capital to finance operations on terms satisfactory to the company and the availability of clearances or approvals of product by federal, state and foreign government authorities. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion